Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16467137 | 0.82 | PIK3CA (0.39) | KDM4EGAAPIK3CAMTORMAPT | |
| SCHEMBL16467103 | 0.82 | OPRK1 (0.40) | PIK3CACNR2MTORGCK | |
| SCHEMBL4672749 | 0.79 | KDM4E (0.49) | KDM4EGAAPIK3CARAF1PIK3R1 | |
| SCHEMBL16467022 | 0.78 | OPRK1 (0.43) | PIK3CAMTORGCK | |
| Hydrochloric Acid SCHEMBL5378200 | 0.78 | KDM4E (0.47) | KDM4EGAAPIK3CARAF1PIK3R1 | |
| SCHEMBL27883277 | 0.78 | GAA (0.47) | KDM4EGAAPIK3CARAF1PIK3R1 | |
| SCHEMBL1724026 | 0.76 | KDM4E (0.51) | KDM4EGAAPIK3CARAF1PIK3R1 | |
| SCHEMBL2144542 | 0.76 | KDM4E (0.46) | KDM4EGAAPIK3CARAF1PIK3R1 | |
| SCHEMBL3544476 | 0.76 | MAPT (0.54) | KDM4EGAAPIK3CACNR2RAF1 | |
| SCHEMBL14910489 | 0.76 | ALDH1A1 (0.52) | MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-02-13 | — | — | US | disclosed |
| US-12054483-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-08-06 | — | — | US | disclosed |
| US-20220041590-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2022-02-10 | — | — | US | disclosed |
| US-20200039989-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2020-02-06 | — | — | US | disclosed |
| EP-2589592-B1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM CORP (JP) | 2018-08-22 | — | — | EP | disclosed |
| CN-102958918-B | Novel tobacco amide derivatives or its salt | FUJIFILM CORP. (JP) | 2015-12-09 | — | — | CN | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895585-B2 | Nicotinamide derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8809371-B2 | — | — | 2014-08-19 | — | — | US | disclosed |
| US-8772320-B2 | — | — | 2014-07-08 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| EP-2589592-A1 | NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF | FUJIFILM Corporation (JP) | 2013-05-08 | — | — | EP | disclosed |
| CN-102958918-A | Novel nicotinamide derivatives or salts thereof | FUJIFILM CORP | 2013-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116430-A1 | NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF | SYK, CD38, BTK | KDM4E 2420/4885GAA 3096/4885PIK3CA 633/4885 |
| US-12528810-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK3, CLK2, CLK1 | KDM4E 2135/4885GAA 4455/4885PIK3CA 2273/4885 |
| US-20200039989-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK1, CLK3 | KDM4E 2963/4885GAA 2689/4885PIK3CA 2787/4885 |
| US-20220041590-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK1, CLK3 | KDM4E 2963/4885GAA 2689/4885PIK3CA 2787/4885 |
| US-12054483-B2 | Small molecule inhibitors of DYRK/CLK and uses thereof | CLK2, CLK1, CLK3 | KDM4E 2963/4885GAA 2689/4885PIK3CA 2787/4885 |
| US-20250051325-A1 | SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF | CLK2, CLK1, CLK3 | KDM4E 2963/4885GAA 2689/4885PIK3CA 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.